Efficacy of nonionic low‐osmolar gadodiamide injection in animals with intracranial mass lesions

Abstract

Gadodiamide injection is a nonionic, low-osmolar formulation of a paramagnetic metal chelate complex consisting of gadodiamide and caldiamide sodium. The efficacy of gadodiamide injection as a magnetic resonance (MR) imaging enhancement medium was evaluated by imaging intracranial 9L-glioma lesions induced in rats and naturally occurring lesions in dogs. T1- and T2-weighted spin-echo images were obtained before and after administration of gadodiamide injection at doses of 0.1 and 0.2 mmol/kg. On the precontrast T1-weighted images, the intracranial lesions were not well seen, appearing isointense to normal brain parenchyma. Although the presence of disease was shown unequivocally on the T2-weighted images, the margins of the masses could not be delineated. Postcontrast T1-weighted images were characterized by marked enhancement of the tumor, with no change in signal intensity in the surrounding edematous brain tissue. Gadodiamide injection was efficacious in identifying areas of blood-brain barrier breakdown associated with intracranial masses.

Click Synthesis and Biologic Evaluation of (R)- and (S)-2-Amino-3-[1-(2-[18F]Fluoroethyl)-1H-[1,2,3]Triazol-4-yl]Propanoic Acid for Brain Tumor Imaging with Positron Emission Tomography

“…In contrast, the BBB is not an issue for in vivo tracer uptake by 9L gliosarcoma cells as intracranially implanted 9L tumors do not have a functional BBB as demonstrated by gadolinium-enhanced magnetic resonance imaging studies. 37,38 However, the differences in the biologic behaviors of the ( R )- and ( S )-enantiomers in the cell uptake assays and the in vivo biodistribution studies provide strong evidence that the high tumor to brain ratios observed with ( S )-[ 18 F] 4 are not due to passive BBB effects alone. Failure to cross the normal BBB may limit the role of ( S )-[ 18 F] 4 for imaging gliomas with relatively intact BBBs, in particular low-grade gliomas.…”